Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1716112 | 0.84 | CYP2C19 (0.53) | CTSSCTSKKCNQ2LMNAALDH1A1 | |
| SCHEMBL18098100 | 0.84 | EPHX1 (0.54) | EPHX1KCNQ2LMNAALDH1A1ALOX5 | |
| SCHEMBL3647916 | 0.83 | ACHE (0.47) | EPHX1CTSSCTSKLMNAALDH1A1 | |
| SCHEMBL2120942 | 0.82 | CTSS (0.49) | EPHX1CTSSCTSKKCNQ2LMNA | |
| SCHEMBL3642653 | 0.81 | FFAR2 (0.50) | EPHX1LMNACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL22322995 | 0.81 | EPHX1 (0.59) | EPHX1LMNABCAT2CYP1A2CYP2D6 | |
| SCHEMBL27774147 | 0.81 | LMNA (0.50) | EPHX1CTSSCTSKKCNQ2LMNA | |
| SCHEMBL9577303 | 0.81 | CTSS (0.48) | EPHX1CTSSCTSKKCNQ2LMNA | |
| Fenbutyramide SCHEMBL1478462 | 0.80 | EPHX1 (0.63) | EPHX1KCNQ2LMNAALDH1A1SMN1; SMN2 | |
| Fenbutyramide SCHEMBL232920 | 0.80 | EPHX1 (0.63) | EPHX1KCNQ2LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105517993-B | Aryl amide kinase inhibitors | 百时美施贵宝公司 | 2018-07-13 | — | — | CN | claimed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | claimed |
| CN-1910144-B | Sulfonamide derivatives for the treatment of diseases | PFIZER LTD | 2010-06-09 | — | — | CN | claimed |
| EP-2185560-A1 | HETEROARYL AMIDE ANALOGUES | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| CN-100548976-C | The sulfone amide derivative that is used for the treatment of disease | PFIZER LTD (US) | 2009-10-14 | — | — | CN | claimed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | claimed |
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | claimed |
| WO-2009023623-A1 | HETEROARYL AMIDE ANALOGUES | H, LUNDBECK A/S (DK) | 2009-02-19 | — | — | WO | claimed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| CN-1934071-A | Carboxamide derivatives useful as adrenergic receptors | PFIZER LTD (US) | 2007-03-21 | — | — | CN | claimed |
| CN-1910144-A | Sulfonamide derivatives for the treatment of diseases | PFIZER LTD (US) | 2007-02-07 | — | — | CN | claimed |
| CN-1910143-A | Sulfonamide derivatives for the treatment of diseases | PFIZER LTD (US) | 2007-02-07 | — | — | CN | claimed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | claimed |
| CN-105517993-B | Aryl amide kinase inhibitors | 百时美施贵宝公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-107108552-A | Heterocyclic kinase inhibitors | 百时美施贵宝公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-2096923-B1 | HETEROARYL AMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-01-22 | — | — | EP | disclosed |
| CN-1910144-A | Sulfonamide derivatives for the treatment of diseases | PFIZER LTD (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | EPHX1 387/4885CTSS 350/4885CTSK 1023/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | EPHX1 1333/4885CTSS 1939/4885CTSK 2250/4885 |
| US-20120190680-A1 | Heteroaryl Amide Analogues | P2RX3, P2RX2, ADORA2A | EPHX1 827/4885CTSS 1480/4885CTSK 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.